We are a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Our development programs are targeted at specific subsets of cancer, combining personalized medicine with companion diagnostics to direct therapeutics to those patients most likely to benefit from them.
We have three product candidates in clinical development: CO-1686, which is in Phase I/II development for the treatment of non-small cell lung cancer; rucaparib, which is in Phase II clinical trials for the treatment of ovarian cancer; and lucitanib, which is commencing Phase II clinical trials for the treatment of breast and lung cancers. We maintain global rights for CO-1686 and rucaparib, and U.S. and Japanese rights to lucitanib.
In addition, we are in the discovery phase for a compound to treat patients with gastrointestinal stromal tumors, or GIST, whose cancer is resistant to current therapies.